Treatment of Klebsiella pneumoniae Carbapenemase–Producing Klebsiella pneumoniae Bacteremia With Meropenem, Colistin, and Ceftazidime-Avibactam

Abstract

Ceftazidime-avibactam is a novel combination antimicrobial agent consisting of a broad-spectrum cephalosporin, ceftazidime, and a non–β-lactam β-lactamase inhibitor, avibactam. This agent has demonstrated activity against resistant gram-negative bacteria, including Klebsiella pneumoniae carbapenemase–producing organisms; however, it is US Food and Drug Administration approved for use in urinary tract and intra-abdominal infections only. We present a case of successful treatment of K. pneumoniae carbapenemase–producing K. pneumoniae bacteremia with a combination of meropenem and colistin followed by ceftazidime-avibactam and colistin.

Combinatorial Drug Therapy for Controlling Pseudomonas aeruginosa and Its Association With Chronic Condition of Diabetic Foot Ulcer

“…109 Ceftazidime and avibactam combination had been seen inhibiting against clinical isolates from urinary tract infection. 110 Intraabdominal infections are generally caused by Pseudomonas and have also been treated with ceftolozane/tazobactam, 111 and metronidazole showed superior results as compared with meropenem 112 and the effect of ceftolozane/tazobactam in case of pulmonary infection due to Pseudomonas species, which certainly makes this antibiotic a more potent alternative. Ceftolozane/tazobactam can be used as a potent example with combination of other antibiofilm agents in order to have maximum impact to overcome drug-resistant bacteria.…”